Oculis develops late stage drug candidates for eye and optic nerve diseases, based in Zug, Switzerland. It last closed at $7.06 on Nov 20, down 5.11% on the day.
AI Auto Pilots
Is OCS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OCS.
From OCS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 4). Last 12 months adds up the four latest quarters. Figures are in CHF. Per share figures are left out because the US listing can represent a different number of shares.
OCS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 8% below its 20 day and 18% below its 50 day average. It is 146% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $6.88, and the nearest resistance the Pivot at $7.16.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 7.9%/day
Key levels
$34.4852 week high+388.4%
$17.35200 day average+145.8%
$10.37100 day average+46.9%
$8.3350 day average+18.0%
$8.04Swing high (Nov 9)+13.9%
$7.6220 day average+7.9%
$7.34Pivot R1+4.0%
$7.16Pivot+1.4%
$7.06Last close
$6.88Pivot S1−2.5%
$6.7852 week low−4.0%
$6.78Swing low (Nov 5)−4.0%
Indicators
RSI (14)
36.20
Weak, oversold below 30
Neutral
MACD
-0.29
Above its signal line
Bullish
Stochastic
28.9
Middle of its range
Neutral
ADX (14)
21.1
Weak trend
Williams %R
-80.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-124.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−5.7%
Change over 10 sessions
Bearish
ATR (14)
$0.56
Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 24.0%/day
Key levels
$34.4852 week high+388.4%
$17.35200 day average+145.8%
$10.37100 day average+46.9%
$8.3350 day average+18.0%
$8.04Swing high (Nov 9)+13.9%
$7.6220 day average+7.9%
$7.34Pivot R1+4.0%
$7.16Pivot+1.4%
$7.06Last close
$6.88Pivot S1−2.5%
$6.7852 week low−4.0%
$6.78Swing low (Nov 5)−4.0%
Indicators
RSI (14)
29.15
Oversold below 30
Oversold
MACD
-3.03
Above its signal line
Bullish
Stochastic
8.9
Near the bottom of its range
Oversold
ADX (14)
31.6
Trending down
Williams %R
-96.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-98.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−33.1%
Change over 10 sessions
Bearish
ATR (14)
$1.69
Typical daily range, 24.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for OCS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OCS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OCS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OCSHow many large options trades hit OCS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OCS in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCS is in one of them and how their past OCS trades turned out.
Oculis is a biopharmaceutical company based in Zug, Switzerland, with operations in the U.S. and Iceland. It develops drug candidates for diseases of the eye and optic nerve. Its pipeline includes OCS-01, an eye drop being studied for diabetic macular edema, Licaminlimab, a topical treatment for dry eye disease, and Privosegtor, a neuroprotective candidate for optic neuritis and a related nerve condition. Its intended customers are patients and eye care doctors.